6fy2

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
==Crystal structure of a V2p-reactive RV144 vaccine-like antibody, CAP228-16H, in complex with a heterologous CAP225 V1V2==
==Crystal structure of a V2p-reactive RV144 vaccine-like antibody, CAP228-16H, in complex with a heterologous CAP225 V1V2==
-
<StructureSection load='6fy2' size='340' side='right' caption='[[6fy2]], [[Resolution|resolution]] 2.30&Aring;' scene=''>
+
<StructureSection load='6fy2' size='340' side='right'caption='[[6fy2]], [[Resolution|resolution]] 2.30&Aring;' scene=''>
== Structural highlights ==
== Structural highlights ==
-
<table><tr><td colspan='2'>[[6fy2]] is a 6 chain structure with sequence from [http://en.wikipedia.org/wiki/9hiv1 9hiv1] and [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FY2 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6FY2 FirstGlance]. <br>
+
<table><tr><td colspan='2'>[[6fy2]] is a 6 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens] and [https://en.wikipedia.org/wiki/Human_immunodeficiency_virus_1 Human immunodeficiency virus 1]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6FY2 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6FY2 FirstGlance]. <br>
-
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
+
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.301&#8491;</td></tr>
-
<tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">IGHV5-51 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), IGLV3-21 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN]), Env ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=11676 9HIV1])</td></tr>
+
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=SO4:SULFATE+ION'>SO4</scene></td></tr>
-
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=6fy2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6fy2 OCA], [http://pdbe.org/6fy2 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6fy2 RCSB], [http://www.ebi.ac.uk/pdbsum/6fy2 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6fy2 ProSAT]</span></td></tr>
+
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6fy2 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6fy2 OCA], [https://pdbe.org/6fy2 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6fy2 RCSB], [https://www.ebi.ac.uk/pdbsum/6fy2 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6fy2 ProSAT]</span></td></tr>
</table>
</table>
-
<div style="background-color:#fffaf0;">
+
== Function ==
-
== Publication Abstract from PubMed ==
+
[https://www.uniprot.org/uniprot/A0A3F2YM25_9HIV1 A0A3F2YM25_9HIV1]
-
The alpha4beta7 integrin is a non-essential HIV-1 adhesion receptor, bound by the gp120 V1V2 domain, facilitating rapid viral dissemination into gut-associated lymphoid tissues. Antibodies blocking this interaction early in infection can improve disease outcome, and V1V2-targeted antibodies were correlated with moderate efficacy reported from the RV144 HIV-1 vaccine trial. Monoclonal alpha4beta7-blocking antibodies recognise two slightly different helical V2 conformations, and current structural data suggests their binding sites are occluded in prefusion envelope trimers. Here, we report cocrystal structures of two alpha4beta7-blocking antibodies from an infected donor complexed with scaffolded V1V2 or V2 peptides. Both antibodies recognised the same helix-coil V2 conformation as RV144 antibody CH58, identifying a frequently sampled alternative conformation of full-length V1V2. In the context of Envelope, this alpha-helical form of V1V2 displays highly exposed alpha4beta7-binding sites, potentially providing a functional role for non-native Envelope on virion or infected cell surfaces in HIV-1 dissemination, pathogenesis, and vaccine design.
+
-
Common helical V1V2 conformations of HIV-1 Envelope expose the alpha4beta7 binding site on intact virions.,Wibmer CK, Richardson SI, Yolitz J, Cicala C, Arthos J, Moore PL, Morris L Nat Commun. 2018 Oct 26;9(1):4489. doi: 10.1038/s41467-018-06794-x. PMID:30367034<ref>PMID:30367034</ref>
+
==See Also==
-
 
+
*[[Antibody 3D structures|Antibody 3D structures]]
-
From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
+
-
</div>
+
-
<div class="pdbe-citations 6fy2" style="background-color:#fffaf0;"></div>
+
-
== References ==
+
-
<references/>
+
__TOC__
__TOC__
</StructureSection>
</StructureSection>
-
[[Category: Human]]
+
[[Category: Homo sapiens]]
-
[[Category: Moore, P L]]
+
[[Category: Human immunodeficiency virus 1]]
-
[[Category: Morris, L]]
+
[[Category: Large Structures]]
-
[[Category: Wibmer, C K]]
+
[[Category: Moore PL]]
-
[[Category: Fab]]
+
[[Category: Morris L]]
-
[[Category: Hiv-1 envelope v1v2]]
+
[[Category: Wibmer CK]]
-
[[Category: Immune system]]
+

Revision as of 07:33, 1 May 2024

Crystal structure of a V2p-reactive RV144 vaccine-like antibody, CAP228-16H, in complex with a heterologous CAP225 V1V2

PDB ID 6fy2

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools